Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ofloxacin is a synthetic fluoroquinolone antibiotic used to treat a wide range of bacterial infections in various parts of the body including the respiratory tract (such as pneumonia and bronchitis), urinary tract (including bladder and kidney infections), skin and soft tissue infections (such as cellulitis), prostatitis (prostate infection), pelvic inflammatory disease and certain sexually transmitted diseases like chlamydia and gonorrhea. It is also used in eye drops for superficial bacterial eye infections and ear drops for otitis media with tympanic membrane perforation[1][2][3][4][5]. Ofloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV—enzymes essential for DNA replication—thereby preventing cell division in bacteria[1][5][7]. It is bactericidal with broad-spectrum activity against both Gram-positive and Gram-negative organisms. Ofloxacin was patented in 1980 by Daiichi Sankyo (then Daiichi Seiyaku) in Japan; it received FDA approval in 1990[1][5]. The drug is available as a generic medication worldwide.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ofloxacin.